ArticleBMC cancer2025
Clinical outcomes and predictive factors of immunotherapy efficacy in non-small-cell lung cancer brain metastases: a comparative study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Safety and efficacy of delivering systemic treatments concomitantly with whole-brain radiotherapy: a prospective, observational, single-institution study.Exploration of targeted anti-tumor therapy · 2026Article
- Predictive value of pre-existing thyroid autoantibodies for PD-1 inhibitor-induced hypothyroidism: a retrospective cohort study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrain metastases (BMs) are common in patients with non-small-cell lung cancer (NSCLC) and remain a major therapeutic challenge. While immune checkpoint inhibitors (ICIs) have improved systemic outcomes, their intracranial efficacy and prognostic determinants in patients with BMs, particularly in comparison with chemotherapy, remains insufficiently characterized.
methodsWe conducted a multicenter, retrospective cohort study including NSCLC patients with BMs who received ICIs or chemotherapy alone. Propensity score matching was performed to balance baseline characteristics between treatment groups. Intracranial and extracranial responses, intracranial progression-free survival (iPFS), extracranial PFS (ePFS), and overall survival (OS) were compared. Logistic regression and Cox proportional hazards models were used to identify prognostic factors associated with treatment response and survival.
resultsIn the matched cohort, patients treated with immunotherapy achieved significantly longer median OS than those receiving chemotherapy (18.9 vs. 13.3 months, p = 0.001), while intracranial and extracranial PFS were not significantly prolonged (median iPFS: 10.4 vs. 9.6 months, p = 0.09; median ePFS: 7.8 vs. 7.1 months, p = 0.06). In the intracranial efficacy–evaluable cohort, the intracranial objective response rate (iORR) was 38.9% vs. 35.2% (p = 0.759), whereas the extracranial objective response rate (eORR) was 45.9% vs. 18.0% (p = 0.006), favoring immunotherapy. Concordance between intracranial and extracranial responses was about 70% across groups. In the immunotherapy cohort, development of immune-related adverse events (irAEs), receipt of stereotactic radiotherapy (SRT), and prior radiotherapy were associated with improved OS. Patients receiving intracranial radiotherapy before ICIs achieved a median OS of 32.3 months versus 19.0 months with concurrent therapy. In the chemotherapy cohort, age ≥ 65 years and multiple brain metastases were associated with inferior survival.
conclusionsThis real-world study suggests that immunotherapy may confer a survival advantage over chemotherapy in NSCLC patients with brain metastases, with efficacy less dependent on baseline factors such as age or performance status. Radiotherapy administered before ICIs appeared to be associated with favorable outcomes, although this observation remains hypothesis-generating given the study limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.